GRI Bio (GRI) Stock: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.42
-0.04 (-2.74%)
▼
5d:
-10.13%
30d:
-25.65%
90d:
-7.19%
WAIT
LOW Confidence
Analysis Updated: Nov 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
9d
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GRI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GRI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.42, which is considered oversold relative to its 30-day fair value range of $1.42 to $1.88.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRI scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.50 (+1167.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRI scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.50 (+1167.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.42 -
$1.88
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1167.1% below Wall St target ($18.50)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
- WARNING: Recommendation downgraded due to -10.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.42 -
$1.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.39
Resistance Level
$1.66
Current Trend
Sideways
Technical data as of
Nov 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.73
Wall Street Target
$18.50
(+1167.1%)
Share & Embed Analysis
Last updated: November 03, 2026 10:50 AM ET
Data refreshes hourly during market hours. Next update: 11:50 AM
Data refreshes hourly during market hours. Next update: 11:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$278 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$107 | 41 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$68 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$131 | 53 HOLD |
